Cellular / Tissue-Based Products (CTPs)
Breaking News! Medicare Holds off Changing Payment for CTPs in the Office-Based Setting!
The Centers for Medicare and Medicaid Services (CMS) has issued the final rule for the 2023 Physician Fee schedule.
Could Proposed Policy Changes in the 2023 Physician Fee Schedule Increase Amputations and Infections in Patients With Wounds?
The Alliance of Wound Care Stakeholdershas urged CMS to remove or delay implementation of the proposed CTP provisions from the final 2023 Physician Fee Schedule until patient access issues can be further studied.
The Unspoken Thing About CTP Use – the Cost of the Patient Copay
CTP use has skyrocketed in the physicians’ office, and now CMS is implementing a strategy to contain those costs.
Tell CMS About Your Experience with the Medicare “Advantage” (sic) Program for Wound Patients
I definitely think Wound care patients and practitioners should comment on the way that MA plans affect access to wound management services.
(Not) Choosing Wisely for Cellular and/or Tissue-Based Products (CTPs)
There will be a lot of whining about how vulnerable patients will get hurt by CMS proposed policy on CTPs – but no discussion about limiting the wasted use that caused CMS to act.
The 2023 Medicare Physician Fee Schedule Proposes Sweeping Changes to Cellular and/or Tissue-Based Products (CTPs)
The proposed rule involves sweeping changes to the way that cellular and/or tissue based products for skin wounds (CTPs) are paid for in the physician office setting.
The Math of Cellular Products in the Hospital Outpatient Department
I feel compelled to explain the math of using CTPs in the hospital-based outpatient department (HOPD).
Estimating the Cost-Effectiveness of Cellular and/or Tissue-Based Products
We need more data on the long-term natural history of wounds treated with SOC and longer follow up of subjects enrolled in RCTs if we are to estimate the cost-effectiveness of CTPs with any accuracy.
A Dirty Little Secret About Social Determinants and Access to Cellular and/or Tissue-Based Products (CTPs)
There has long been concern that payer status influences access to CTPs. This seems a valid area of concern.
From Today’s Wound Clinic: The Handwriting on the Wall for Wound Management
Re-printed from Today's Wound Clinic We are at an important crossroads in the field of wound management. From the perspective of new technologies, the future is bright. Unfortunately, the future of...
The Health Economic Impact of Living Cell Tissue Products (and Why This Matters) – Guest Blog by Dr. Helen Gelly
Guest blog post by Dr. Helen Gelly Using the claims data from Medicare that are publicly available, a newly published study which I co-authored looked at various parameters that will eventually...
Decreasing the Disadvantages of Medicare Advantage Plans When Patients Need a Cellular Product
An increasing percentage of my wound center patients have Medicare Advantage plans offered by private payers. As I’ve discussed on previous blogs, it’s getting very hard to use cellular...
It’s 2019 But I Need the 2015 Certified Electronic Health Record?
In 2019, the new standard is the “2015 Edition CEHRT.”
